Diplo TRT: How His Testosterone Therapy Compares to Similar Public Figures

What Diplo Has Said About TRT

Diplo has confirmed TRT use publicly, not through tabloid inference. In podcast appearances, he described using testosterone as part of his health and performance maintenance routine. His framing was matter-of-fact: he treats it as a medical tool, not a shortcut.

That directness matters. Most celebrity health discussions rely on before-and-after photos and speculation. Diplo's self-disclosure gives clinicians and patients a named, on-record example to discuss without inference.

What He Said, Precisely

Diplo described TRT in the context of biohacking and general wellness optimization. He has not, to date, released specific lab values or dosing protocols publicly. Any specific numbers attributed to him beyond his general confirmation would be inference and are labeled as such throughout this article.

Why Public Figures Disclose TRT

The stigma around testosterone therapy has decreased meaningfully since roughly 2015, when direct-to-consumer TRT telehealth companies expanded access. Figures like Joe Rogan discussed TRT on record years before Diplo, helping normalize the conversation. A 2021 analysis published in the Journal of Clinical Endocrinology and Metabolism noted that testosterone prescriptions in the United States increased by approximately 500% between 2000 and 2011 before plateauing, reflecting both broader awareness and regulatory attention [1].

The Clinical Basis for TRT: Who Actually Qualifies

TRT is indicated for men with confirmed symptomatic hypogonadism, defined as low serum testosterone combined with signs or symptoms such as fatigue, decreased libido, loss of lean mass, or depressed mood. The American Urological Association (AUA) guideline states: "Testosterone therapy is indicated in men with symptomatic hypogonadism with consistently low testosterone levels." The threshold is total testosterone <300 ng/dL on at least two morning measurements [2].

Prevalence in Men Diplo's Age Bracket

Diplo was born in 1978, placing him in his mid-40s at the time of his public disclosures. Hypogonadism prevalence rises with age. The Massachusetts Male Aging Study found that total testosterone declines at roughly 1 to 2% per year after age 30, and free testosterone declines faster, at approximately 2 to 3% per year [3]. By the time men reach their mid-40s, a clinically meaningful subset will have total testosterone below the 300 ng/dL threshold.

NHANES data show that hypogonadism (defined as total testosterone <300 ng/dL) affects roughly 12% of men aged 50 to 79 in the United States [4]. In the 40 to 49 age range, prevalence is lower but not negligible, particularly in men with obesity, sleep apnea, or high physiological stress, all conditions relevant in a touring musician's lifestyle.

Symptoms That Prompt Testing

The Endocrine Society's clinical practice guideline lists the following as conditions warranting testosterone measurement: unexplained fatigue, decreased libido, erectile dysfunction, loss of body hair, reduced muscle mass, depressive symptoms, and osteoporosis in younger men [5]. A man in his 40s experiencing several of these would meet criteria for evaluation, regardless of celebrity status.

Standard TRT Protocols: What the Evidence Shows

TRT is not a single drug or route. Approved options in the United States include intramuscular (IM) injections, subcutaneous injections, transdermal gels, transdermal patches, buccal tablets, intranasal gel, and long-acting subcutaneous pellets. Each has a different pharmacokinetic profile, adherence pattern, and side-effect consideration.

Injectable Testosterone: The Most Common Form

Testosterone cypionate and testosterone enanthate are the two most prescribed injectable forms in the U.S. Testosterone cypionate is typically dosed at 100 to 200 mg IM every 7 to 14 days, or 50 to 100 mg weekly via subcutaneous injection. Weekly subcutaneous dosing produces more stable serum levels and is now preferred by many prescribers to reduce the trough-to-peak swing associated with biweekly IM dosing [6].

The FDA approved testosterone cypionate (Depo-Testosterone) for hypogonadism. The prescribing information specifies a dose range of 50 to 400 mg every 2 to 4 weeks IM, though clinical practice has moved toward more frequent, lower-dose protocols to minimize supraphysiologic peaks [7].

Topical Gels

AndroGel 1.62% and Testim are among the branded transdermal options. These are applied daily to clean, dry skin (shoulders, upper arms) and provide steady-state testosterone within 24 to 48 hours. A multicenter trial published in the Journal of Clinical Endocrinology and Metabolism (N=274) found that AndroGel 1.62% at 40.5 mg/day raised mean total testosterone to 421 ng/dL from a baseline of 237 ng/dL after 182 days of treatment [8].

Monitoring Requirements

No TRT protocol is appropriately managed without follow-up labs. The AUA guideline and Endocrine Society both specify: total testosterone, free testosterone, hematocrit, PSA, and LH/FSH at 3 and 6 months after initiation, then annually [2][5]. Hematocrit above 54% requires dose reduction or temporary discontinuation due to polycythemia risk.

How Diplo's Situation Compares to Similar Public Figures

Several other prominent men have discussed TRT or testosterone use publicly. Comparing their contexts, motivations, and communication styles shows where Diplo fits in a broader cultural and clinical picture.

Joe Rogan

Joe Rogan has discussed TRT extensively on The Joe Rogan Experience. He has mentioned using testosterone as part of a protocol that has, at various points, included human growth hormone and other compounds. Rogan's framing is performance and longevity oriented. His openness pre-dates most mainstream TRT discourse and arguably shifted public perception of the therapy from something associated exclusively with illness toward something associated with optimization.

Clinically, Rogan's self-reported approach appears to involve more aggressive optimization targets than standard replacement therapy. Standard TRT aims to restore testosterone to the mid-normal range, roughly 400 to 700 ng/dL. Optimization protocols targeting the upper quartile (700 to 900 ng/dL) are sometimes used but sit outside strict guideline-based replacement.

Andrew Huberman

Andrew Huberman, neuroscientist and host of the Huberman Lab podcast, has discussed testosterone optimization in detail across multiple episodes. He has spoken about clomiphene citrate (clomid) as an alternative to exogenous testosterone, specifically because clomiphene stimulates endogenous LH and FSH secretion, preserving testicular function and fertility. A randomized controlled trial in Fertility and Sterility (N=100) found that clomiphene citrate 25 mg every other day raised mean testosterone from 226 ng/dL to 610 ng/dL at 12 months without suppressing spermatogenesis [9].

Huberman's approach represents a distinct clinical pathway compared to exogenous TRT. For younger men concerned about fertility, clomiphene or human chorionic gonadotropin (hCG) co-administration are evidence-supported alternatives or adjuncts.

Athletes and Retired Professionals

Multiple retired professional athletes, particularly in the NFL and combat sports, have disclosed TRT use post-career. Testosterone use in active competition falls under anti-doping regulations. The World Anti-Doping Agency (WADA) bans exogenous testosterone in competition regardless of medical need, though therapeutic use exemptions (TUEs) exist for documented hypogonadism. For non-competing figures like Diplo, no such regulatory constraint applies.

The Touring Musician Context

Diplo's specific lifestyle, sustained touring, international travel across time zones, irregular sleep, high performance pressure, adds physiological context that is clinically relevant. Chronic sleep deprivation suppresses LH pulsatility, which in turn reduces testicular testosterone output. A study published in JAMA (N=10 healthy young men) found that restricting sleep to 5 hours per night for one week reduced daytime testosterone levels by 10 to 15% [10]. For a touring artist with years of accumulated sleep disruption, that effect may be compounded.

This does not confirm Diplo's diagnosis or indicate that his TRT use was driven specifically by these factors. It does illustrate that lifestyle context is clinically meaningful when evaluating middle-aged men for hypogonadism.

Risks, Benefits, and What the Data Actually Show

TRT's evidence base is substantial but not uniformly positive. Patients and clinicians weighing the therapy should engage with both sides.

Cardiovascular Signal: TRAVERSE Trial

The TRAVERSE trial, published in the New England Journal of Medicine in 2023 (N=5,246), was specifically designed to evaluate cardiovascular safety of testosterone replacement in men with hypogonadism and elevated cardiovascular risk. The primary composite outcome (major adverse cardiovascular events) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group, a non-inferiority result [11]. The trial also found a statistically significant increase in atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism in the testosterone group. These findings led to updated FDA labeling language in 2024 regarding cardiovascular and thromboembolic risk.

Benefits with Confirmed Hypogonadism

For men with confirmed hypogonadism, TRT produces consistent improvements in several measured outcomes. A Cochrane systematic review (32 RCTs, N=1,792) found that TRT significantly improved sexual function scores, mood, and bone mineral density compared to placebo [12]. Lean mass increases were modest but consistent. The same review found no significant effect on quality-of-life measures in men with normal baseline testosterone, which underlines why diagnosis confirmation before treatment matters.

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. LH and FSH fall, testicular testosterone production ceases, and sperm production declines, often to azoospermia within 3 to 4 months of TRT initiation. For men who may want biological children, this is a critical pre-treatment discussion. Recovery of spermatogenesis after TRT discontinuation typically takes 6 to 18 months and is not guaranteed [13].

Co-administration of hCG at 500 to 1,000 IU every 2 to 3 days can maintain intratesticular testosterone and partially preserve spermatogenesis during TRT.

What Monitoring Looks Like in Practice

A properly managed TRT protocol does not end at the prescription pad. The Endocrine Society's 2018 clinical practice guideline specifies the following monitoring schedule [5]:

• Testosterone level (trough, for injections): 3 to 6 months after initiation, then annually
• Hematocrit: 3 to 6 months after initiation, then annually. Hold therapy if hematocrit rises above 54%
• PSA: Baseline, then 3 to 6 months, then per age-appropriate prostate cancer screening guidelines
• Bone mineral density: At baseline in men with osteoporosis risk, then every 1 to 2 years
• Mood and symptom reassessment: Each visit

Men who begin TRT without this follow-up infrastructure are under-served. Telehealth TRT providers vary widely in how rigorously they implement monitoring. Patients should confirm that any prescribing platform requires labs before initiation and at regular intervals.

Should a 46-Year-Old Man Consider TRT?

Not automatically. The decision requires confirmed low testosterone on two separate morning draws, documented symptoms, absence of contraindications (active prostate cancer, hematocrit above 50% at baseline, untreated severe sleep apnea, or desire for fertility without adjunct therapy), and a monitoring plan.

A 46-year-old man in good physical condition with testosterone in the 350 to 450 ng/dL range and no significant symptoms is not a TRT candidate by current guidelines, even if peers or public figures are using it.

The Endocrine Society is explicit: "We recommend against making a diagnosis of androgen deficiency or starting testosterone therapy in men who have not had at least two testosterone measurements confirming low values." [5]

That standard applies whether the patient is a touring musician, a podcast host, or anyone else.

The Broader Shift in Male HRT Culture

TRT normalization is real and measurable. A study in JAMA Internal Medicine found that testosterone prescriptions among commercially insured men in the U.S. Increased from 0.81% in 2001 to 2.91% in 2011, with the largest growth in men aged 40 to 64 who had no prior testosterone testing [14]. That last detail is the concern: therapy without diagnosis.

Public figures discussing TRT openly shifts the cultural baseline. That shift has dual effects. On one side, men with genuine hypogonadism who previously avoided seeking care may now feel less stigma doing so. On the other side, men with normal testosterone may pursue therapy based on identity with optimized public figures rather than medical need.

Diplo's public statements do not detail his lab values or diagnosis. His case should not be read as a template. It should be read as a prompt to have the conversation with a clinician who can order the right tests.